CJC-1295 / RESEARCH
The CJC-1295 research record: what was measured, in which species, at which dose.
Human pharmacokinetics, the preserved-pulse finding, the preclinical bioconjugation data, and the reported safety signals — each claim tagged by evidence strength and cited.
How CJC-1295 acts on the GH/IGF-1 axis
CJC-1295 is a long-acting GHRH analog, and its mechanism is the GHRH receptor itself. The molecule binds the growth-hormone-releasing hormone receptor — a class B G-protein-coupled receptor on anterior-pituitary somatotrophs — and activates Gs/cAMP/PKA signaling that drives CREB-mediated GH gene transcription and the pulsatile release of stored GH [3]. The released GH reaches hepatic GH receptors, triggers JAK2/STAT5 signaling, and raises circulating IGF-1, the liver-derived hormone that mediates much of GH's downstream action [3].
The analog's persistence is structural. Four substitutions (D-Ala2, Gln8, Ala15, Leu27) block dipeptidylpeptidase-IV cleavage and other degradation, and the DAC modification covalently tethers the peptide to serum albumin so it resists clearance [2]. The original Endocrinology study confirmed that the hGRF(1-29)-albumin bioconjugate still activates the GRF receptor on the rat anterior pituitary, establishing that conjugation extended duration without abolishing receptor activity [2].
What the research reports CJC-1295 does to the GH/IGF-1 axis
In healthy adults, CJC-1295 produced sustained, dose-dependent elevation of both GH and IGF-1 from a single subcutaneous dose. Doses of 30 or 60 micrograms per kilogram drove 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days [1]. With multiple doses, IGF-1 remained above baseline up to 28 days, and the estimated half-life was 5.8 to 8.1 days [1].
The preserved-pulse result is the mechanistically notable one. A single 60- or 90-microgram-per-kilogram dose in healthy young men raised trough/basal GH roughly 7.5-fold, mean GH about 46%, and IGF-1 about 45% one week later, with pulse frequency and amplitude unchanged [3]. This matters because the GH axis is naturally episodic, and earlier human work showed that episodic GHRH delivery is more effective than continuous infusion at generating GH pulses [7]. That a continuously present long-acting analog still leaves the pulse pattern intact is precisely why this result was published — the sustained stimulus raised the baseline without erasing the rhythm [3]. A separate proteomic study found that CJC-1295 produced reproducible serum protein-profile shifts in healthy men, with an immunoglobulin/albumin-fragment signal that correlated linearly with IGF-1 — candidate biomarkers of GH/IGF-1 axis activation [5].
Measured outcomes in CJC-1295 studies (GH and IGF-1)
The measured outcomes in CJC-1295 studies are pharmacokinetic and endocrine, not body-composition. The human readouts are the +7.5-fold basal GH, the +45% IGF-1 at one week, and the 5.8-to-8.1-day half-life already described [1][3]. The preclinical readout is the bioconjugation advantage: in rats, CJC-1295 showed a 4-fold increase in GH area-under-the-curve over two hours versus unconjugated hGRF(1-29), remained detectable in plasma beyond 72 hours, and was confirmed stable against dipeptidylpeptidase-IV in vitro [2].
A mouse-genetics study closed the loop on whether this translates to GH-axis-dependent growth. In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary GH mRNA [4]. The interpretation is direct: the long-acting analog's once-daily schedule was sufficient to restore growth in an animal that otherwise lacks GHRH signaling [4]. What is absent from this record is any large efficacy trial in healthy adults — the human data are early-phase pharmacokinetics, and outcome claims beyond GH/IGF-1 kinetics outrun the published evidence.
Reported and Theoretical Side Effects of CJC-1295 in the Literature
Reported and theoretical side effects of CJC-1295 cluster around GH-axis stimulation, and the controlled long-term safety data simply do not exist. Because GH drives renal sodium reabsorption, sustained GH/IGF-1 elevation can cause fluid retention and edema, and can affect insulin sensitivity — these are recognized consequences of GH-axis activation rather than CJC-1295-specific trial findings [1]. FDA briefing materials prepared for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295.
The most-cited theoretical concern is the IGF-1/cancer signal: epidemiology has linked higher circulating IGF-1 to a modestly increased risk of certain cancers, which is relevant to any agent that durably raises IGF-1. The original long-acting DAC development program (ConjuChem) was discontinued, and a Phase 2 trial in HIV-associated visceral obesity (NCT00267527) did not advance; a patient death during the development era is frequently cited in connection with the halted program, though a causal link to CJC-1295 was not established in the public record. The honest summary is that the peer-reviewed safety database in healthy adults is thin and short-term, and CJC-1295 remains unapproved for human use.
Where CJC-1295 sits among GHRH analogs
As a GHRH analog, CJC-1295 shares its receptor and backbone with sermorelin and the approved drug tesamorelin, and the broader class has been characterized in detail by recent reviews [14]. The 2024/2025 Nature Reviews Endocrinology review of GHRH and its analogs covers the receptor pharmacology, the rationale for long-acting analog design, and the investigational landscape this molecule belongs to [14].
The class's analytical history is also well documented, because GHRH analogs are doping-relevant. CJC-1295 was definitively identified by high-resolution LC-MS/MS as the active ingredient in an unknown "GHRH" pharmaceutical preparation seized in an anti-doping context [6], earlier qualitative identification of GHRH analogs in human plasma was demonstrated by immunoaffinity purification with LC-MS [12], and a 2021 review surveyed the advances in detecting GHRH synthetic analogs in sport [11]. The class has even been studied for tissue effects beyond the pituitary: agonistic GHRH analogs promoted wound healing in experimental models [13]. CJC-1295 is prohibited at all times in sport under WADA Section S2.